Variable MLC stimulatory capacity of neoplastic B and non-B/non-T lymphocytes expressing HLA-DR antigens. 1982

A A Bom-van Noorloos, and I Schreuder, and G de Groot-Swings, and J Ubels-Postma, and A E von dem Borne, and C J Melief

Neoplastic cells from patients with a variety of B- or non-B/non-T-lymphoid malignancies, including chronic lymphocytic leukemia, various histologic types of non-Hodgkin lymphoma and acute lymphocytic leukemia, showed strong variation with respect to stimulatory capacity in mixed lymphocyte culture (MLC). MLC stimulatory capacity was either normal or strongly decreased in comparison with that of normal lymphocytes despite the expression of HLA-DR antigens and p23,30 ("Ia-like") determinants on the tumor cells of all patients. Strongly decreased stimulatory capacity of HLA-DR-positive tumor cells could not be ascribed to suppressive activity of the tumor cells. Tumor cells from three patients with a T-cell malignancy failed to stimulate in MLC and did not react with anti-p23,30 serum. The decreased stimulatory capacity of many DR-positive neoplastic cells is ascribed either to altered membrane presentation of DR antigens or to the absence of MLC stimulatory determinants specified by genes closely linked to, but different from, those coding for DR.

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D007959 Lymphocyte Culture Test, Mixed Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens. Leukocyte Culture Test, Mixed,Mixed Lymphocyte Culture Test,Mixed Lymphocyte Reaction,Mixed Leukocyte Culture Test,Mixed Leukocyte Reaction,Leukocyte Reaction, Mixed,Leukocyte Reactions, Mixed,Lymphocyte Reaction, Mixed,Lymphocyte Reactions, Mixed,Mixed Leukocyte Reactions,Mixed Lymphocyte Reactions
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011947 Receptors, Antigen, B-Cell IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment. Antigen Receptors, B-Cell,B-Cell Antigen Receptor,B-Cell Antigen Receptors,Surface Immunoglobulin,Immunoglobulins, Membrane-Bound,Immunoglobulins, Surface,Membrane Bound Immunoglobulin,Membrane-Bound Immunoglobulins,Receptors, Antigen, B Cell,Surface Immunoglobulins,Antigen Receptor, B-Cell,Antigen Receptors, B Cell,B Cell Antigen Receptor,B Cell Antigen Receptors,Bound Immunoglobulin, Membrane,Immunoglobulin, Membrane Bound,Immunoglobulin, Surface,Immunoglobulins, Membrane Bound,Membrane Bound Immunoglobulins,Receptor, B-Cell Antigen,Receptors, B-Cell Antigen
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D005802 Genes, MHC Class II Genetic loci in the vertebrate major histocompatibility complex that encode polymorphic products which control the immune response to specific antigens. The genes are found in the HLA-D region in humans and include H-2M, I-A, and I-E loci in mice. Class II Genes,Genes, Class II,Genes, HLA Class II,MHC Class II Genes,Class II Gene,Gene, Class II
D006684 HLA-DR Antigens A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS. HLA-DR,Antigens, HLA-DR,HLA DR Antigens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A A Bom-van Noorloos, and I Schreuder, and G de Groot-Swings, and J Ubels-Postma, and A E von dem Borne, and C J Melief
March 1980, Tissue antigens,
A A Bom-van Noorloos, and I Schreuder, and G de Groot-Swings, and J Ubels-Postma, and A E von dem Borne, and C J Melief
March 1982, Journal of immunology (Baltimore, Md. : 1950),
A A Bom-van Noorloos, and I Schreuder, and G de Groot-Swings, and J Ubels-Postma, and A E von dem Borne, and C J Melief
October 1983, Tissue antigens,
A A Bom-van Noorloos, and I Schreuder, and G de Groot-Swings, and J Ubels-Postma, and A E von dem Borne, and C J Melief
August 1988, Muscle & nerve,
A A Bom-van Noorloos, and I Schreuder, and G de Groot-Swings, and J Ubels-Postma, and A E von dem Borne, and C J Melief
November 1978, Vnitrni lekarstvi,
A A Bom-van Noorloos, and I Schreuder, and G de Groot-Swings, and J Ubels-Postma, and A E von dem Borne, and C J Melief
January 1989, The American journal of pathology,
A A Bom-van Noorloos, and I Schreuder, and G de Groot-Swings, and J Ubels-Postma, and A E von dem Borne, and C J Melief
February 1994, Transplantation,
A A Bom-van Noorloos, and I Schreuder, and G de Groot-Swings, and J Ubels-Postma, and A E von dem Borne, and C J Melief
June 1983, Proceedings of the National Academy of Sciences of the United States of America,
A A Bom-van Noorloos, and I Schreuder, and G de Groot-Swings, and J Ubels-Postma, and A E von dem Borne, and C J Melief
February 1982, British journal of haematology,
A A Bom-van Noorloos, and I Schreuder, and G de Groot-Swings, and J Ubels-Postma, and A E von dem Borne, and C J Melief
December 1979, Transplantation proceedings,
Copied contents to your clipboard!